Merad Miriam

MERAD Miriam

Professor of Immunology and Research Center Director Icahn School of Medicine at Mount Sinai, United States

Origins & Education

Miriam Merad was born in 1969 in Paris, in a family where medicine and science held a prominent place. She is the daughter of Kheireddine Merad, a professor of cardiology, and Rachida Chiali, a professor of toxicology. This family environment undoubtedly played a decisive role in her orientation towards a scientific and medical career.

Her academic journey illustrates her international character and quest for excellence. She began her medical studies at the University of Algiers, where she acquired the solid foundations of her medical training. Continuing her path in France, she completed her residency at Paris-Diderot University, deepening her clinical knowledge and developing her medical expertise.

Driven by scientific ambition and attracted by research opportunities in the United States, Miriam Merad emigrated across the Atlantic to enroll at Stanford University. It was there that she completed her doctorate in the laboratory of Prof. Edgar Engleman, a defining experience that would orient her career towards immunology and research on immune system cells.

Scientific Career

Miriam Merad's scientific career truly took off in 2004, when she was first recruited to the Mount Sinai School of Medicine. Her ascent within this prestigious institution testifies to the excellence of her research work and her significant contribution to the advancement of knowledge in immunology. She was promoted to the rank of associate professor in 2007, then to the position of full professor in 2010. In 2014, she was awarded an endowed chair in cancer immunology, thus consecrating her position as a leader in this field of research.

Miriam Merad's research has been pioneering in identifying the mechanisms that control the development and functional identity of tissue-resident dendritic cells and macrophages. She notably identified the lineage of tissue-resident macrophages and discovered their particular role in the physiology and pathophysiology of organs, a major advance in understanding the immune system.

She has also established the contribution of this macrophage lineage to cancer evolution and inflammatory diseases, thus paving the way for the development of innovative treatments targeting macrophages in these indications. Moreover, her work on dendritic cells, a group of cells that control adaptive immunity, led her to identify a new subgroup of dendritic cells, now considered a key target for antitumor and antiviral immunity.

Currently, Miriam Merad directs the "Precision Institute at the Icahn School of Medicine" (PrIISM), an initiative aimed at bringing immunology discoveries to the clinic. PrIISM is distinguished by its interdisciplinary approach, combining research programs in immunology with biology, medicine, technology, physics, mathematics, and computational biology, with the goal of improving our understanding of human immunology.

She has also founded the "Human Immune Monitoring Center" at Mount Sinai, one of the world's leading research centers. This center uses cutting-edge single-cell technology to understand the role of immune cells in serious human diseases or in response to treatments, thus illustrating the innovative and technologically advanced approach of her research.

A prolific author, Miriam Merad has published more than 200 articles and analyses in renowned scientific journals, and her work has been cited hundreds of times, testifying to the considerable impact of her research on the international scientific community.

Distinctions & Recognition

Miriam Merad's exceptional career has been marked by numerous distinctions that testify to the importance and impact of her scientific contributions.

In 2020, she was elected to the prestigious National Academy of Sciences of the United States, a supreme recognition of her pioneering work in immunology and its influence on the advancement of scientific knowledge.

Her contribution to cancer research was recognized by the awarding of the William B. Coley Award for Distinguished Research in Tumor Immunology, a distinction that highlights the importance of her work in understanding the immune mechanisms involved in the development and progression of tumors.

Recently, on April 18, 2024, she received the prestigious ARC Foundation Léopold-Griffuel Prize, an international recognition of her contributions to cancer research.

Miriam Merad is also an elected member of the American Society for Clinical Investigation, an honorary society that recognizes researchers who have made significant contributions to the understanding of human diseases.

Her leadership and vision in the field of immunology are also recognized by her appointment as President of the International Union of Immunological Societies (IUIS), a role that allows her to influence the directions of immunology research on a global scale.

Furthermore, her research has benefited from significant funding from the National Institutes of Health (NIH), testifying to the confidence of this institution in the quality and relevance of her work. She is also part of several NIH consortia, thus participating in large-scale collaborative research initiatives.

Impact & Influence

The impact of Miriam Merad's work on medical science and immunology in particular is considerable and multidimensional.

Her fundamental discoveries on dendritic cells and macrophages have transformed our understanding of the immune system and its role in various pathologies, notably cancer. By identifying new cell subgroups and elucidating their specific functions, she has paved the way for innovative therapeutic approaches targeting these cells to treat inflammatory diseases and cancers.

Her work on the tumor microenvironment and on how tumors inhibit the normal anti-tumor functions of immune cells has also significantly contributed to our understanding of tumor escape mechanisms and has inspired the development of new immunotherapy strategies.

As the director of the Precision Institute at the Icahn School of Medicine and founder of the Human Immune Monitoring Center, Miriam Merad has also influenced the way immunology research is organized and conducted. Her interdisciplinary approach, combining immunology with other scientific disciplines and using cutting-edge technologies, has established a new paradigm for translational research in immunology.

Her leadership position as President of the International Union of Immunological Societies allows her to influence the priorities and directions of immunology research on a global scale, thus helping to shape the future of this crucial scientific field.

Moreover, as a female scientist of Algerian origin who has reached the highest levels of excellence and recognition in American academia, Miriam Merad represents an inspiring model for young scientists, especially for women and people from diverse backgrounds. Her international journey, from Algeria to France and then to the United States, also illustrates the richness and value of international scientific exchanges.

Finally, her constant commitment to translating fundamental discoveries into clinical applications, as evidenced by the creation of PrIISM, reflects her vision of science in the service of medicine and patients, with a concrete impact on improving healthcare and developing new therapies.

Learn More

To deepen your knowledge about Miriam Merad and her work, you can consult:

• Her Wikipedia page
• Her interview on France Inter (April 18, 2024)
• The website of the Merad Laboratory at the Icahn School of Medicine at Mount Sinai
• Her scientific publications available on PubMed or Google Scholar
• The website of the Human Immune Monitoring Center at Mount Sinai
• The National Academy of Sciences resources regarding her work